TTY Biopharm Co Ltd
TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan, the United States, and internationally. The company operates through the Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, Other Business Unit, and Re-investment Business Unit segments. It off… Read more
TTY Biopharm Co Ltd (4105) - Total Assets
Latest total assets as of June 2025: NT$10.67 Billion TWD
Based on the latest financial reports, TTY Biopharm Co Ltd (4105) holds total assets worth NT$10.67 Billion TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
TTY Biopharm Co Ltd - Total Assets Trend (2017–2024)
This chart illustrates how TTY Biopharm Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
TTY Biopharm Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
TTY Biopharm Co Ltd's total assets of NT$10.67 Billion consist of 53.3% current assets and 46.7% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 25.5% |
| Accounts Receivable | NT$1.33 Billion | 12.3% |
| Inventory | NT$1.27 Billion | 11.7% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how TTY Biopharm Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: TTY Biopharm Co Ltd's current assets represent 53.3% of total assets in 2024, an increase from 52.6% in 2017.
- Cash Position: Cash and equivalents constituted 25.5% of total assets in 2024, up from 15.2% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 12.3% of total assets.
TTY Biopharm Co Ltd Competitors by Total Assets
Key competitors of TTY Biopharm Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
TTY Biopharm Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - TTY Biopharm Co Ltd generates 0.54x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, TTY Biopharm Co Ltd generates $ 13.34 in net profit.
TTY Biopharm Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.77 | 1.85 | 1.73 |
| Quick Ratio | 1.38 | 1.48 | 1.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$2.50 Billion | NT$ 2.55 Billion | NT$ 2.03 Billion |
TTY Biopharm Co Ltd - Advanced Valuation Insights
This section examines the relationship between TTY Biopharm Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.03 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | 10.0% |
| Total Assets | NT$10.86 Billion |
| Market Capitalization | $486.74 Million USD |
Valuation Analysis
Below Book Valuation: The market values TTY Biopharm Co Ltd's assets below their book value (0.04 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: TTY Biopharm Co Ltd's assets grew by 10.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for TTY Biopharm Co Ltd (2017–2024)
The table below shows the annual total assets of TTY Biopharm Co Ltd from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$10.86 Billion | +10.00% |
| 2023-12-31 | NT$9.87 Billion | +2.86% |
| 2022-12-31 | NT$9.60 Billion | +3.27% |
| 2021-12-31 | NT$9.30 Billion | -0.69% |
| 2020-12-31 | NT$9.36 Billion | -2.01% |
| 2019-12-31 | NT$9.55 Billion | +5.52% |
| 2018-12-31 | NT$9.05 Billion | -4.77% |
| 2017-12-31 | NT$9.51 Billion | -- |